Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > Fibrosis: a key feature of Fabry disease with potential therapeutic implications
Publication

Publications

Fibrosis: a key feature of Fabry disease with potential therapeutic implications

Title
Fibrosis: a key feature of Fabry disease with potential therapeutic implications
Type
Another Publication in an International Scientific Journal
Year
2013
Authors
Weidemann, F
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Sanchez Nino, MD
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Politei, J
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
João Paulo Oliveira
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page Without ORCID
Wanner, C
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Warnock, DG
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Ortiz, A
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Journal
Vol. 8
Final page: 116
ISSN: 1750-1172
Publisher: Springer Nature
Other information
Authenticus ID: P-006-89H
Abstract (EN): Fabry disease is a rare X-linked hereditary disease caused by mutations in the AGAL gene encoding the lysosomal enzyme alpha-galactosidase A. Enzyme replacement therapy (ERT) is the current cornerstone of Fabry disease management. Involvement of kidney, heart and the central nervous system shortens life span, and fibrosis of these organs is a hallmark of the disease. Fibrosis was initially thought to result from tissue ischemia secondary to endothelial accumulation of glycosphingolipids in the microvasculature. However, despite ready clearance of endothelial deposits, ERT is less effective in patients who have already developed fibrosis. Several potential explanations of this clinical observation may impact on the future management of Fabry disease. Alternative molecular pathways linking glycosphingolipids and fibrosis may be operative; tissue injury may recruit secondary molecular mediators of fibrosis that are unresponsive to ERT, or fibrosis may represent irreversible tissue injury that limits the therapeutic response to ERT. We provide an overview of Fabry disease, with a focus on the assessment of fibrosis, the clinical consequences of fibrosis, and recent advances in understanding the cellular and molecular mechanisms of fibrosis that may suggest novel therapeutic approaches to Fabry disease.
Language: English
Type (Professor's evaluation): Scientific
No. of pages: 12
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same journal

Aggressive mature natural killer cell neoplasms: from epidemiology to diagnosis (2013)
Another Publication in an International Scientific Journal
Lima, M
Therapeutic strategies based on modified U1 snRNAs and chaperones for Sanfilippo C splicing mutations (2014)
Article in International Scientific Journal
Matos L; Canals I; Dridi L; Choi Y; Maria João Ribeiro; Jordan P; Pshezhetsky AV; Grinberg D; Alves S A; Vilageliu L
Stable or improved neurological manifestations during miglustat therapy in patients from the international disease registry for Niemann-Pick disease type C: An observational cohort study (2015)
Article in International Scientific Journal
Patterson, MC; Mengel, E; Vanier, MT; Schwierin, B; Muller, A; Cornelisse, P; Pineda, M; Amado Fondo, A; Amraoui, Y; Andria, G; Arellano, M; Audoin, B; Azcona, C; Barr, C; Baruteau, J; Baumgartner, C; Bell, L; Bembi, B; Benneddif, K; Bernard, G...(mais 179 authors)
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document (2015)
Article in International Scientific Journal
Biegstraaten, M; Arngrimsson, R; Barbey, F; Boks, L; Cecchi, F; Deegan, PB; Feldt Rasmussen, U; Geberhiwot, T; Germain, DP; Hendriksz, C; Hughes, DA; Kantola, I; Karabul, N; Lavery, C; Linthorst, GE; Mehta, A; van de Mheen, E; João Paulo Oliveira; Parini, R; Ramaswami, U...(mais 14 authors)
Pyruvate dehydrogenase complex deficiency: updating the clinical, metabolic and mutational landscapes in a cohort of Portuguese patients (2020)
Article in International Scientific Journal
Pavlu Pereira, H; Silva, MJ; Florindo, C; Sequeira, S; Ferreira, AC; Duarte, S; Rodrigues, AL; Janeiro, P; Oliveira, A; Gomes, D; Bandeira, A; Martins, E; Gomes, R; Soares, S; de Almeida, IT; Vicente, JB; Rivera, I

See all (9)

Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-07-12 at 14:31:27 | Privacy Policy | Personal Data Protection Policy | Whistleblowing